Probiotic Supplementation in Patients with Alzheimer's Dementia - An Explorative Intervention Study - PubMed (original) (raw)
Probiotic Supplementation in Patients with Alzheimer's Dementia - An Explorative Intervention Study
Friedrich Leblhuber et al. Curr Alzheimer Res. 2018.
Abstract
Background: Dysbiosis of intestinal microbiota in the elderly can cause a leaky gut, which may result in silent systemic inflammation and promote neuroinflammation - a relevant pathomechanism in the early course of Alzheimer's disease.
Objective: The rebalancing of the microbiome could benefically impact on gut inflammation and immune activation.
Methods: In this study, routine laboratory tests in twenty outpatients (9 females, 11 males, aged 76.7 ± 9.6 years) with Alzheimer's disease were investigated. The mean Mini Mental State Examination score was 18.5 ± 7.7. Biomarkers of immune activation - serum neopterin and tryptophan breakdown - as well as gut inflammation markers and microbiota composition in fecal specimens were analyzed in 18 patients before and after probiotic supplementation for 4 weeks.
Results: After treatment a decline of fecal zonulin concentrations and an increase in Faecalibacterium prausnitzii compared to baseline were observed. At the same time, serum kynurenine concentrations increased (p <0.05). Delta values (before - after) of neopterin and the kynurenine to tryptophan ratios (Kyn/Trp) correlated significantly (p <0.05).
Conclusion: Results show that the supplementation of Alzheimer's disease patients with a multispecies probiotic influences gut bacteria composition as well as tryptophan metabolism in serum. The correlation between Kyn/Trp and neopterin concentrations points to the activation of macrophages and/or dendritic cells. Further studies are warranted to dissect the potential consequences of Probiotic supplementation in the course of Alzheimer's disease.
Keywords: Alzheimer`s disease; Faecalibacterium prausnitzii; Gut microbiota; brain-gut axis; dementia; neopterin; neuroinflammation; probiotics..
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Figures
Fig. (1)
The proposed role of immune activation arms in Alzheimer’s disease (AD). (A) Oxidative stress is associated with Th1-type immunity and suppresses the Th2-arm, and vice versa. Both, the composition of diet and the microbiome, influence immune homeostasis in a physiological range. While the establishment of tolerance requires more Th2-like conditions, a deviation to pro-oxidative Th1 is necessary for an efficient removal of pathogens, tumor cells and amyloid proteins. The preponderance of a strong reductive milieu, e.g., due to excessive intake of food antioxidants and likewise the presence of chronic oxidative stress are crucial in the progression of a variety of disorders. (B) Corresponding hypothesis: It is suggested that in early stages of AD there is an inefficient clearance from amyloid precursors, potentially due to overwhelming Th2 conditions which in the course of disease development from mild cognitive impairment (MCI) to AD promote an activation of counteracting Th1-type immune mechanisms that also lead to neuronal damage.
Similar articles
- Impact of High-Dose Multi-Strain Probiotic Supplementation on Neurocognitive Performance and Central Nervous System Immune Activation of HIV-1 Infected Individuals.
Ceccarelli G, Brenchley JM, Cavallari EN, Scheri GC, Fratino M, Pinacchio C, Schietroma I, Fard SN, Scagnolari C, Mezzaroma I, Vullo V, d'Ettorre G. Ceccarelli G, et al. Nutrients. 2017 Nov 21;9(11):1269. doi: 10.3390/nu9111269. Nutrients. 2017. PMID: 29160817 Free PMC article. - Lowered Levels of Carbonyl Proteins after Vitamin B Supplementation in Patients with Mild Cognitive Impairment and Alzheimer's Disease.
Rommer PS, Fuchs D, Leblhuber F, Schroth R, Greilberger M, Tafeit E, Greilberger J. Rommer PS, et al. Neurodegener Dis. 2016;16(3-4):284-9. doi: 10.1159/000441565. Epub 2015 Nov 21. Neurodegener Dis. 2016. PMID: 26587902 Clinical Trial. - Probiotics ameliorate intestinal pathophysiology in a mouse model of Alzheimer's disease.
Kaur H, Nagamoto-Combs K, Golovko S, Golovko MY, Klug MG, Combs CK. Kaur H, et al. Neurobiol Aging. 2020 Aug;92:114-134. doi: 10.1016/j.neurobiolaging.2020.04.009. Epub 2020 Apr 18. Neurobiol Aging. 2020. PMID: 32417748 Free PMC article. - Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer's disease.
Kesika P, Suganthy N, Sivamaruthi BS, Chaiyasut C. Kesika P, et al. Life Sci. 2021 Jan 1;264:118627. doi: 10.1016/j.lfs.2020.118627. Epub 2020 Oct 22. Life Sci. 2021. PMID: 33169684 Review. - The Microbiota-Gut-Brain Axis and Alzheimer's Disease: Neuroinflammation Is to Blame?
Megur A, Baltriukienė D, Bukelskienė V, Burokas A. Megur A, et al. Nutrients. 2020 Dec 24;13(1):37. doi: 10.3390/nu13010037. Nutrients. 2020. PMID: 33374235 Free PMC article. Review.
Cited by
- Reverse engineering the Gut-Brain Axis and microbiome-metabolomics for symbiotic/pathogenic balance in neurodegenerative diseases.
Munir MU, Ali SA, Chung KHK, Kakinen A, Javed I, Davis TP. Munir MU, et al. Gut Microbes. 2024 Jan-Dec;16(1):2422468. doi: 10.1080/19490976.2024.2422468. Epub 2024 Nov 10. Gut Microbes. 2024. PMID: 39523450 Free PMC article. Review. - Alzheimer's Disease-Derived Outer Membrane Vesicles Exacerbate Cognitive Dysfunction, Modulate the Gut Microbiome, and Increase Neuroinflammation and Amyloid-β Production.
Wei S, Ma X, Chen Y, Wang J, Hu L, Liu Z, Mo L, Zhou N, Chen W, Zhu H, Yan S. Wei S, et al. Mol Neurobiol. 2024 Nov 8. doi: 10.1007/s12035-024-04579-6. Online ahead of print. Mol Neurobiol. 2024. PMID: 39514171 - Investigation of the Neuroprotective Action of Japanese Sake Yeast on Dementia Type of Alzheimer Disease in Rats: Behavioral and Neurobiochemical Assessment.
Haghipanah M, Ghalami F, Saadat M, Abbasi-Maleki S, Gholizadeh Salmani RH, Budde T, Moradikor N. Haghipanah M, et al. NeuroSci. 2023 Jan 19;4(1):45-53. doi: 10.3390/neurosci4010006. eCollection 2023 Mar. NeuroSci. 2023. PMID: 39484298 Free PMC article. - Gut Microbiome in Alzheimer's Disease: from Mice to Humans.
Liang C, Pereira R, Zhang Y, Rojas OL. Liang C, et al. Curr Neuropharmacol. 2024;22(14):2314-2329. doi: 10.2174/1570159X22666240308090741. Curr Neuropharmacol. 2024. PMID: 39403057 Free PMC article. Review. - The intestinal microbiota as an ally in the treatment of Alzheimer's disease.
Sehn Hilgert S, Dias DPM. Sehn Hilgert S, et al. Gut Microbiome (Camb). 2023 Jun 19;4:e9. doi: 10.1017/gmb.2023.8. eCollection 2023. Gut Microbiome (Camb). 2023. PMID: 39295910 Free PMC article. Review.
References
- Fratiglioni L., De Ronchi D., Aguero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging. 1999;15(5):365–375. - PubMed
- McGeer P.L., McGeer E.G. Inflammation, autotoxicity and Alzheimer disease. Neurobiol. Aging. 2001;22:799–809. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical